Merestinib
Merestinib is a small molecule inhibitor with potential antineoplastic activity. It is primarily researched for its ability to inhibit multiple receptor tyrosine kinases (RTKs), which are known to play crucial roles in various forms of cancer. Merestinib targets the MET (mesenchymal-epithelial transition) receptor, AXL, and MKNK1/2 among others, disrupting cancer cell signaling and proliferation.
Mechanism of Action[edit]
Merestinib works by inhibiting the activity of several receptor tyrosine kinases, including MET, AXL, and MKNK1/2. The MET proto-oncogene is particularly significant in the progression of many cancers, including non-small cell lung cancer (NSCLC), gastric cancer, and renal cell carcinoma. By blocking the MET signaling pathway, merestinib can inhibit tumor growth and metastasis. AXL receptor tyrosine kinase is involved in tumor cell survival, growth, migration, and angiogenesis. Inhibition of AXL by merestinib can lead to reduced tumor aggressiveness and increased sensitivity to other anticancer agents.
Clinical Trials[edit]
Merestinib has been evaluated in various phases of clinical trials for its efficacy and safety in treating different types of cancers. One of the notable studies includes its investigation in combination with other therapeutic agents for the treatment of NSCLC and other solid tumors. The outcomes of these studies are crucial for understanding the potential therapeutic window of merestinib in oncology.
Pharmacokinetics[edit]
The pharmacokinetic profile of merestinib includes its absorption, distribution, metabolism, and excretion characteristics in the human body. Understanding these parameters is essential for optimizing dosing regimens to achieve maximum therapeutic efficacy while minimizing adverse effects.
Adverse Effects[edit]
As with many anticancer agents, merestinib can cause a range of adverse effects. These may include, but are not limited to, fatigue, nausea, vomiting, and hematologic abnormalities such as anemia and thrombocytopenia. Monitoring and management of these side effects are critical components of patient care during treatment with merestinib.
Future Directions[edit]
Research continues to explore the full potential of merestinib in cancer therapy, including its use in combination with other treatments. The identification of biomarkers that predict response to merestinib could also enhance its application in precision medicine, allowing for more targeted and effective cancer treatment strategies.
| Chemotherapy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This Chemotherapy related article is a stub.
|
-
Merestinib
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
